Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases

A method of treating a subject who would benefit from metabolizing fructose-lysine to thereby reduce formation of Advanced Glycation End products (AGEs) and/or increase butyric acid, butyrate and/or a derivative of butyrate in the gastrointestinal tract of the subject, the method comprising:

• administering to the subject a bacterium comprising:
• a lysine pathway gene set that enables the bacterium to convert L-lysine into butyric acid, butyrate and/or a derivative of butyrate, and
• a fructose-lysine uptake and degradation operon that enables the bacterium to convert fructose-lysine into butyric acid, butyrate, and/or derivative of butyrate,
• wherein the lysine pathway gene set encodes at least one of Lysine 2.3-aminomutase, L-beta-lysine 5.6-aminomutase alpha subunit, L-beta-lysine 5,6-aminomutase beta subunit, 3.5-diaminobexanoate dehydrogenase, 3-keto-5-aminohexanoate cleavage enzyme, 3-aminobutyryl-CoA ammonia-lyase, butyrateacetoacetate CoA-transferase subunit A, butyrate-acetoacetate GoA-transferase subunit B, and acetyl-CoA:acetoacetyl-CoA transferase;
• and
• wherein the fructose-lysine uptake and degradation operon encode at least one of fructose-lysine kinase, fructosamine deglycase, ABC transporter periplasmic spermidine putrescine-binding protein PotD, spermidine putrescine ABC transporter permease component PotC, spermidine putrescine ABC transporter permease component PotB, and putrescine transport ATP-binding protein PotA.